Progressive	JJ
transforming-growth-factor-beta1-induced	JJ
lung	NN
fibrosis	NN
is	VBZ
blocked	VBN
by	IN
an	DT
orally	RB
active	JJ
ALK5	NN
kinase	NN
inhibitor	NN
.	.

Pulmonary	JJ
fibrosis	NN
is	VBZ
characterized	VBN
by	IN
chronic	JJ
scar	NN
formation	NN
and	CC
deposition	NN
of	IN
extracellular	JJ
matrix	NN
,	,
resulting	VBG
in	IN
impaired	JJ
lung	NN
function	NN
and	CC
respiratory	JJ
failure	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
associated	VBN
with	IN
pronounced	JJ
morbidity	NN
and	CC
mortality	NN
and	CC
responds	VBZ
poorly	RB
to	TO
known	VBN
therapeutic	JJ
interventions	NNS
;	:
there	EX
are	VBP
no	DT
known	JJ
drugs	NNS
that	WDT
effectively	RB
block	VBP
or	CC
reverse	VBP
progressive	JJ
fibrosis	NN
.	.

Transforming-growth-factor-beta	NN
(	(
TGF-beta	NN
)	)
is	VBZ
known	VBN
to	TO
mediate	VB
extracellular	JJ
matrix	NN
gene	NN
regulation	NN
and	CC
appears	VBZ
to	TO
be	VB
a	DT
major	JJ
player	NN
in	IN
both	CC
the	DT
initiation	NN
and	CC
progression	NN
of	IN
IPF	NN
.	.

TGF-beta	NN
mediates	VBZ
its	PRP$
biological	JJ
effects	NNS
through	IN
members	NNS
of	IN
a	DT
family	NN
of	IN
activin	NN
receptor-like	JJ
kinases	NNS
(	(
ALK	NN
)	)
.	.

We	PRP
have	VBP
used	VBN
a	DT
gene	NN
transfer	NN
model	NN
of	IN
progressive	JJ
TGF-beta1-induced	JJ
pulmonary	JJ
fibrosis	NN
in	IN
rats	NNS
to	TO
study	VB
a	DT
newly	RB
described	VBN
orally	RB
active	JJ
small	JJ
molecular	JJ
weight	NN
drug	NN
that	WDT
is	VBZ
a	DT
potent	JJ
and	CC
selective	JJ
inhibitor	NN
of	IN
the	DT
kinase	NN
activity	NN
of	IN
ALK5	NN
,	,
the	DT
specific	JJ
TGF-beta	NN
receptor	NN
.	.

We	PRP
show	VBP
that	IN
the	DT
drug	NN
inhibits	VBZ
the	DT
induction	NN
of	IN
fibrosis	NN
when	WRB
administered	VBN
at	IN
the	DT
time	NN
of	IN
initiation	NN
of	IN
fibrogenesis	NN
and	CC
,	,
most	RBS
important	JJ
,	,
blocks	VBZ
progressive	JJ
fibrosis	NN
when	WRB
administered	VBN
transiently	RB
to	TO
animals	NNS
with	IN
established	JJ
fibrosis	NN
.	.

These	DT
data	NNS
show	VBP
promise	NN
of	IN
the	DT
development	NN
of	IN
an	DT
effective	JJ
therapeutic	JJ
intervention	NN
for	IN
IPF	NN
and	CC
that	IN
inhibition	NN
of	IN
chronic	JJ
progressive	JJ
fibrosis	NN
may	MD
be	VB
achieved	VBN
by	IN
blocking	VBG
TGF-beta	NN
receptor	NN
activation	NN
.	.

